Last reviewed · How we verify
SAM-531 and gemfibrozil — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
SAM-531 and gemfibrozil (SAM-531 and gemfibrozil) — Wyeth is now a wholly owned subsidiary of Pfizer.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| SAM-531 and gemfibrozil TARGET | SAM-531 and gemfibrozil | Wyeth is now a wholly owned subsidiary of Pfizer | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- SAM-531 and gemfibrozil CI watch — RSS
- SAM-531 and gemfibrozil CI watch — Atom
- SAM-531 and gemfibrozil CI watch — JSON
- SAM-531 and gemfibrozil alone — RSS
Cite this brief
Drug Landscape (2026). SAM-531 and gemfibrozil — Competitive Intelligence Brief. https://druglandscape.com/ci/sam-531-and-gemfibrozil. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab